LATEST ARTICLES
Details emerge of first Huntington’s disease gene therapy clinical trial
UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein...
EIP Pharma Initiates New Study with Neflamapimod for the Treatment of...
EIP Pharma, Inc., a CNS-focused therapeutics company, today announced the initiation of a new Phase 2 proof-of-concept study evaluating neflamapimod as a treatment for...
Sangamo Therapeutics Announces Nature Medicine Publication Detailing the Activity of Disease...
Jul. 1, 2019-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the publication of a manuscript describing the activity of allele-selective zinc finger...
UNIVERSITY
Distinct clinical profiles of Huntington’s disease can be associated with two...
Cognitive-motor and psychiatric profiles of Huntington's disease show a different pattern of brain alterations
The identification of specific neural signatures can help develop specific biomarkers...
BGU Scientists Duplicate Blood-Brain Barrier Outside the Body
Scientists can't make a living copy of your brain outside your body. That's the stuff of science fiction. But in a new study, they...
A new molecular mechanism could explain the origins of the depressive...
About 40 % of the affected patients with Huntington’s disease –a neurodegenerative pathology- show depression symptoms, even in early stages before the apparition of...
Smartphone app can help diagnose a rare disease
Team of researchers at Kaunas University of Technology (KTU), Lithuania have created a mobile application, which helps recognise early symptoms of a rare Huntington’s...
HDBUZZ
Details emerge of first Huntington’s disease gene therapy clinical trial
UniQure announces key details of its planned trial to assess the safety and ability of AMT-130 gene therapy to lower the problematic huntingtin protein...
Fresh Updates from First Huntingtin Lowering Study Publication
Hot off the presses - New publication gives more details about the results of Ionis and Roche's safety study with a Huntingtin-lowering ASO
oday saw...
ARTICLES
IONIS-HTTRx
